Thrombocythaemia Myelofibrosis Therapeutic and Drug Pipeline Review H2

Global Thrombocythaemia Myelofibrosis Drugs and Companies Pipeline Review H2 2016

PUNE, INDIA, January 23, 2017 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for Thrombocythaemia Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombocythaemia Myelofibrosis and features dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/619251-thrombocythaemia-myelofibrosis-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
- The report provides a snapshot of the global therapeutic landscape of Thrombocythaemia Myelofibrosis
- The report reviews pipeline therapeutics for Thrombocythaemia Myelofibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Thrombocythaemia Myelofibrosis therapeutics and enlists all their major and minor projects
- The report assesses Thrombocythaemia Myelofibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Thrombocythaemia Myelofibrosis

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Thrombocythaemia Myelofibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Thrombocythaemia Myelofibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Thrombocythaemia Myelofibrosis Overview 6
Therapeutics Development 7
Pipeline Products for Thrombocythaemia Myelofibrosis - Overview 7
Pipeline Products for Thrombocythaemia Myelofibrosis - Comparative Analysis 8
Thrombocythaemia Myelofibrosis - Therapeutics under Development by Companies 9
Thrombocythaemia Myelofibrosis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Thrombocythaemia Myelofibrosis - Products under Development by Companies 12
Thrombocythaemia Myelofibrosis - Companies Involved in Therapeutics Development 13
Celgene Corporation 13
Gilead Sciences, Inc. 14
Incyte Corporation 15
JW Pharmaceutical Corporation 16
Nippon Shinyaku Co., Ltd. 17
Novartis AG 18
Pfizer Inc. 19
Thrombocythaemia Myelofibrosis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
buparlisib hydrochloride - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
CWP-291 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
glasdegib - Drug Profile 34
Product Description 34

Access Report @ https://www.wiseguyreports.com/reports/619251-thrombocythaemia-myelofibrosis-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here